Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Donepezil/memantine extended release - Adamas Pharmaceuticals

Next Previous
Drug Profile

Donepezil/memantine extended release - Adamas Pharmaceuticals

Alternative Names: ADS-8703; ADS-8704; Arimenda; donepezil HCl/memantine ER; donepezil HCl/Namenda XR®; MDX-8704; memantine ER/donepezil HCl; memantine ER/donepezil IR; Memantine/donepezil; Namenda; Namenda XR®/donepezil HCl; Namzaric

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adamas Pharmaceuticals
  • Developer AbbVie; Adamas Pharmaceuticals
  • Class Analgesics; Antidementias; Antiparkinsonians; Antispastics; Indans; Nootropics; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Alzheimer's disease
  • No development reported Dementia

Most Recent Events

  • 24 Nov 2021 Adamas Pharmaceuticals has been acquired by Supernus Pharmaceuticals
  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 31 Jan 2019 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top